Table 2.

Factors associated with achievement of complete cytogenetic response (CCyR) (restricted to 44 patients eligible for response assessment).

Characteristic		Number achieving CCyR or better (%)	p-value univariate 2-sided pearson ch-sq
Reason for cessation of last-line of therapy
	Resistance (n = 16)	5 (31%)	<0.001
	Intolerance (n = 28)	24 (86%)
Prior response to any TKI (CCyR)
	Achieved CCyR (n = 32)	27 (84%)	<0.001
	No prior CCyR (n = 12)	2 (17%)
Prior ponatinib use
	No prior ponatinib (n = 19)	15 (79%)	0.112
	Prior ponatinib (n = 25)	14 (56%)
Prior ponatinib response
	Ponatinib intolerant (n = 17)	12 (71%)	0.032
	Ponatinib resistant (n = 8)	2 (25%)
History of any prior BSNV
	No prior BSNV (n = 25)	19 (76%)	0.105
	Prior BSNV (n = 19)	10 (53%)
Prior history of T315I-BSNV
	No prior T315I BSNV (n = 35)	24 (69%)	0.463
	Prior T315I BSNV (n = 9)	5 (56%)
Prior history non-T315I-BSNV
	No prior non-T315I BSNV (n = 32)	24 (75%)	0.038
	Prior non-T315I BSNV (n = 12)	5 (42%)

CCyR complete cytogenetic response, Ch-sq chi-squared, TKI tyrosine kinase inhibitor, BSNV, BCR::ABL1 single nucleotide variants.